noom and glp-1 Launches Microdosing for Longevity Noom to offer GLP-1 drug

LUPKIN: And that's on top of already-high insurance premiums

Percentages are rounded up to one decimal place BID two times a day, BMI body mass index, BMOD intensive behavior modification, GLP-1RA glucagon-like peptide 1 receptor agonist, IBT intensive behavioral therapy, NR not reported, OAD oral antihyperglycemic drug, PT phentermine-topiramate, QD once-daily, TID three times per day a Based on patients achieving 5% weight loss during the run-in period b NB16: sustained-release naltrexone 16 mg per day plus sustained-release bupropion 360 mg per day combined in fixed-dose tablets

Those with significant medical co-morbidities, prior CSF diversion procedures, neurovascular stenting or optic nerve sheath fenestration, those currently using GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors or taking drugs that could reduce ICP were excluded

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with improved long-term graft survival and overall survival, according to study data

It's the same drug, but Wegovy can be prescribed in larger doses

Danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, will undergo dose optimization studies in the second half of 2024 as Pfizer seeks to evaluate multiple doses of the formulation which they hope will inform the registration-enabling studies